Thiazolidinedione Class of Anti-Diabetic Drugs Modulate Nuclear Receptor CAR Function

Shashi Singh, R. Tyagi
{"title":"Thiazolidinedione Class of Anti-Diabetic Drugs Modulate Nuclear Receptor CAR Function","authors":"Shashi Singh, R. Tyagi","doi":"10.18311/JER/2017/20188","DOIUrl":null,"url":null,"abstract":"The human body has developed a defence system to prevent the accumulation of endogenous (bile acids, steroids, cholesterol metabolites, neurotransmitters, etc.) as well as exogenous (xenobiotics, clinical drugs, etc.) small molecules at toxic levels. This task is accomplished by ‘drug metabolism and disposition (DMD) machinery’ which entails phase I and phase II enzymes, and phase III transporter proteins. The components of this machinery act in a coordinated manner to biotransform and facilitate the elimination of small toxic molecules from the cellular milieu. Constitutive androstane receptor (CAR), a member of the nuclear receptor superfamily, acts as one of the major transcriptional regulators of the DMD machinery. Prescription of combination therapy is a common regimen during the treatment of diverse metabolic disorders and infectious diseases. In such combination therapies one drug may modulate the expression of genes of DMD, influencing the metabolism of another co-administered drug. This leads to decreased bioavailability or increased toxicity of the latter. Evaluation of drug-drug interactions (DDIs) has now become a major safety concern during drug discovery and development processes. Pre-assessment of the small molecules for modulatory effects on CAR and induction of the components of DMD can resolve the safety concerns, treatment failures and drug withdrawals due to the harmful DDIs. In the present study, we have followed a ‘reverse approach’ to assess CAR activation by drugs previously withdrawn from clinical practices. We selected three redundant members of thiazolidinedione family of anti-diabetic drugs and examined their potential in regulation of CAR and its target gene CYP2B6. These drugs showed differential transcriptional activation of CAR. Two of the TZD i.e., rosiglitazone and pioglitazone enhanced CAR activity by behaving as receptor ligands while the other (troglitazone) did not influence the receptor function and was justly withdrawn since it inflicted cytotoxicity.","PeriodicalId":15664,"journal":{"name":"Journal of Endocrinology and Reproduction","volume":"37 1","pages":"27-34"},"PeriodicalIF":0.0000,"publicationDate":"2017-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Endocrinology and Reproduction","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.18311/JER/2017/20188","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

The human body has developed a defence system to prevent the accumulation of endogenous (bile acids, steroids, cholesterol metabolites, neurotransmitters, etc.) as well as exogenous (xenobiotics, clinical drugs, etc.) small molecules at toxic levels. This task is accomplished by ‘drug metabolism and disposition (DMD) machinery’ which entails phase I and phase II enzymes, and phase III transporter proteins. The components of this machinery act in a coordinated manner to biotransform and facilitate the elimination of small toxic molecules from the cellular milieu. Constitutive androstane receptor (CAR), a member of the nuclear receptor superfamily, acts as one of the major transcriptional regulators of the DMD machinery. Prescription of combination therapy is a common regimen during the treatment of diverse metabolic disorders and infectious diseases. In such combination therapies one drug may modulate the expression of genes of DMD, influencing the metabolism of another co-administered drug. This leads to decreased bioavailability or increased toxicity of the latter. Evaluation of drug-drug interactions (DDIs) has now become a major safety concern during drug discovery and development processes. Pre-assessment of the small molecules for modulatory effects on CAR and induction of the components of DMD can resolve the safety concerns, treatment failures and drug withdrawals due to the harmful DDIs. In the present study, we have followed a ‘reverse approach’ to assess CAR activation by drugs previously withdrawn from clinical practices. We selected three redundant members of thiazolidinedione family of anti-diabetic drugs and examined their potential in regulation of CAR and its target gene CYP2B6. These drugs showed differential transcriptional activation of CAR. Two of the TZD i.e., rosiglitazone and pioglitazone enhanced CAR activity by behaving as receptor ligands while the other (troglitazone) did not influence the receptor function and was justly withdrawn since it inflicted cytotoxicity.
噻唑烷二酮类抗糖尿病药物调节核受体CAR功能
人体已经发展出一种防御系统,以防止内源性(胆汁酸、类固醇、胆固醇代谢物、神经递质等)和外源性(异种药物、临床药物等)小分子在毒性水平上的积累。这项任务是通过“药物代谢和处置(DMD)机制”完成的,其中需要I期和II期酶以及III期转运蛋白。该机制的组成部分以协调的方式进行生物转化,并促进从细胞环境中消除小有毒分子。组成型雄烷受体(CAR)是核受体超家族的成员之一,是DMD机制的主要转录调节因子之一。联合用药是多种代谢性疾病和感染性疾病治疗中的常用方案。在这种联合治疗中,一种药物可以调节DMD基因的表达,影响另一种共给药药物的代谢。这导致后者的生物利用度降低或毒性增加。药物相互作用(ddi)的评价现已成为药物发现和开发过程中一个主要的安全问题。预先评估小分子对CAR的调节作用和诱导DMD成分可以解决由有害ddi引起的安全问题、治疗失败和药物停药。在目前的研究中,我们采用了一种“反向方法”来评估以前从临床实践中退出的药物对CAR的激活。我们选择了三个多余的抗糖尿病药物噻唑烷二酮家族成员,并研究了它们在调节CAR及其靶基因CYP2B6方面的潜力。这些药物显示出CAR的转录激活差异。其中两种TZD,即罗格列酮和吡格列酮通过充当受体配体来增强CAR活性,而另一种(曲格列酮)不影响受体功能,并因其造成细胞毒性而被合理地撤回。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信